Figure 2From: Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder Posterior predictive check for change from baseline in number of urgency urinary incontinence (UUI) episodes after taking placebo or fesoterodine 4 mg, 8 mg, or 12 mg.Back to article page